Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.79)
# 1,760
Out of 4,834 analysts
43
Total ratings
33.33%
Success rate
52.16%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.23 | +1,688.62% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $4.69 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $4.89 | +390.80% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $17.59 | +457.13% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $20.04 | +523.75% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.80 | +900.00% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.39 | +696.65% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $0.65 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $7.55 | +7,847.02% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $192.90 | -58.96% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $56.17 | +175.95% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.35 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.56 | +602.25% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4,080 | $2.20 | +185,354.55% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $1.67 | +108,008.11% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $41.49 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.56 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.73 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.25 | +19,608.32% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.93 | +22,800.76% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.29 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $21.19 | +962.07% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.11 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.51 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.23
Upside: +1,688.62%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.69
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $4.89
Upside: +390.80%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $17.59
Upside: +457.13%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $20.04
Upside: +523.75%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.80
Upside: +900.00%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.39
Upside: +696.65%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.65
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $7.55
Upside: +7,847.02%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $192.90
Upside: -58.96%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $56.17
Upside: +175.95%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.35
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.56
Upside: +602.25%
Apr 30, 2021
Initiates: Outperform
Price Target: $4,080
Current: $2.20
Upside: +185,354.55%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $1.67
Upside: +108,008.11%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $41.49
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.56
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $6.73
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.25
Upside: +19,608.32%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $3.93
Upside: +22,800.76%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.29
Upside: -
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $21.19
Upside: +962.07%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.11
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.51
Upside: -